Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHONQUER: ivosidenib versus placebo in advanced conventional chondrosarcoma
ChiCTR2500101989Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chondrosarcoma comparing Ivosidenib group with Placebo group (2 arms). Primary endpoint: Progression-free survival in Grade 1 and Grade 2 participants. Planned start May 2025; status: not yet recruiting.
02
Drugs
ivosidenib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on ChiCTR2500101989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101989.